apollo

Select Address

0
  • Login

About ACALABRUTINIB

ACALABRUTINIB is a tyrosine kinase inhibitor or cancer growth inhibitor that is primarily used to treat people with mantle cell lymphoma (MCL) who have had at least one prior treatment for their malignancy (cancer), as well as adults with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). Cancer is caused by a genetic mutation that causes our cells to divide uncontrollably and spread into neighbouring tissues.

ACALABRUTINIB contains Acalabrutinib, a tyrosine kinase inhibitor. Tyrosine kinases are enzymes in the body that transmit signals to cells, telling them to grow and divide. Acalabrutinib inhibits these signals to cancer cells. Cells die when their signals are disrupted. This could help to slow the progression of the cancer.

To treat your condition effectually, continue using ACALABRUTINIB for as long as your doctor has prescribed it. The most common adverse reactions are anaemia (lack of blood), neutropenia (low count of neutrophils), upper respiratory tract infection, thrombocytopenia (Low platelet level), headache, diarrhoea, and musculoskeletal pain. You should talk to your doctor if you persistently experience these side effects.

It is recommended not to use if you are hypersensitive to any component present in ACALABRUTINIB and suffer from Severe Hepatic Impairment. ACALABRUTINIB can cause fetal harm when administered to a pregnant woman. It is critical not to become pregnant or get pregnant while undergoing therapy and for several months after the treatment. Using effective contraceptive methods is recommended while on therapy with ACALABRUTINIB. Contact your doctor immediately if you or your partner becomes pregnant while undergoing therapy. Breastfeeding is usually not advised during this treatment. Alcohol should be avoided during treatment with this medicine. Safety and effectiveness in children have not been established.

Uses of ACALABRUTINIB

Mantle cell lymphoma (MCL), chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Medicinal Benefits

ACALABRUTINIB is primarily used to treat people with mantle cell lymphoma (MCL) who have had at least one prior treatment for their malignancy, as well as adults with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). ACALABRUTINIB contains Acalabrutinib, a tyrosine kinase inhibitor. Tyrosine kinases are enzymes in the body that send signals to cells, directing them to grow and divide. Acalabrutinib blocks these signals to cancer cells. Cancer cells die when their signals are interrupted. This could help to delay the progression of the cancer.

Directions for Use

ACALABRUTINIB should be swallowed as a whole with a glass of water. Do not crush, chew, or break the tablets. The doctor determines the dose and duration based on your health condition.

Storage

Store in a cool and dry place away from sunlight

Side Effects of ACALABRUTINIB

  • Feeling sick (nausea)
  • Being sick (vomiting)
  • Fatigue (
  • Anaemia (lack of blood)
  • Neutropenia (low count of neutrophils)
  • Upper respiratory tract infection
  • Thrombocytopenia (low platelet level)
  • Headache
  • Diarrhea
  • Musculoskeletal pain (myalgia)
  • Abdominal pain
  • Fatigue (tiredness)
  • Bruising
  • Rash
  • Haemorrhage (bleeding)
  • Epistaxis (nosebleed)

In-Depth Precautions and Warning

Drug Warnings

Before taking the ACALABRUTINIB, inform your doctor about all your medical conditions, sensitivities, and medications you are using. If you are a woman capable of having children, you should use an effective method of contraception during Acalabrutinib treatment and for at least one week after the last dose. If you are a man, you should use a barrier method of contraception to prevent your partner from becoming pregnant while taking Acalabrutinib and for at least one week after the last dose. Unless the doctor suggests, do not use any other medicine, including herbal or vitamin supplements.

Drug Interactions

Drug-Drug Interactions: ACALABRUTINIB may interact with Blood thinner medications (e.g. abciximab, apixaban), Vaccinations (e.g. BCG vaccine), Nonsteroidal Anti-inflammatory drugs (e.g. bromfenac, ibuprofen), HIV medications (e.g. cobicistat), Anticancer medications (e.g. dasatinib), antifungal medications (e.g. fluconazole) and medicines decreasing the amount of acid made in the stomach (e.g. esomeprazole).

Drug-Food Interactions: Avoid the intake of alcoholic beverages, grapefruit and grapefruit juice.

Drug-Disease Interactions: ACALABRUTINIB interacts with disease conditions, including arrhythmias, bleeding disorder, kidney or liver illness, infections (Bacterial/Fungal/Protozoal/Viral), Immunodeficiency, and Bone Marrow Depression/Low Blood Counts.

Drug-Drug Interactions Checker List:

  • ABCIXIMAB
  • APIXABAN
  • BCG VACCINE
  • BROMFENAC
  • IBUPROFEN
  • COBICISTAT
  • DASATINIB
  • ESOMEPRAZOLE
  • FLUCONAZOLE
  • Safety Advice

    • Safety Warning

      Alcohol

      unsafe

      Avoid alcohol consumption while on treatment with ACALABRUTINIB.

    • Safety Warning

      Pregnancy

      unsafe

      ACALABRUTINIB should not be used during pregnancy. So, inform your doctor if you are pregnant or suspect pregnancy. You or your partner must use a reliable form of contraception to prevent pregnancy while taking these medications.

    • Safety Warning

      Breast Feeding

      unsafe

      ACALABRUTINIB should not be used in breastfeeding. Discuss with your doctor if you have any concerns.

    • Safety Warning

      Driving

      caution

      ACALABRUTINIB does not influence the ability to drive or use machines. However, go only if you are alert, as the ACALABRUTINIB may cause tiredness in some people.

    • Safety Warning

      Liver

      caution

      Avoid using ACALABRUTINIB in patients with severe hepatic impairment. The safety of ACALABRUTINIB has not been evaluated in patients with moderate or severe hepatic impairment. So, caution should be exercised while using ACALABRUTINIB in patients with liver impairment. If you have a pre-existing or a history of liver disease, inform your doctor before taking the ACALABRUTINIB. Your doctor will weigh the benefits and potential risks before prescribing ACALABRUTINIB.

    • Safety Warning

      Kidney

      caution

      Caution should be exercised while using ACALABRUTINIB in patients with kidney impairment. If you have a pre-existing or a history of kidney disease, inform your doctor before taking the ACALABRUTINIB. Your doctor will weigh the benefits and potential risks before prescribing ACALABRUTINIB.

    • Safety Warning

      Children

      caution

      Safety and effectiveness in patients below the age of 18 years have not been established. Hence, use is not recommended.

    Habit Forming

    No

    Diet & Lifestyle Advise

    • After your treatment begins, several dietary adjustments can help you control side effects.
    • Anyone suffering from a chronic illness, including cancer, should consume foods high in protein, healthy fats, whole grains, and vitamins and minerals.
    • Plant-based proteins are among the greatest meals during chemotherapy or other cancer treatments. They have the highest concentrations of vitamins and minerals, such as nuts, seeds, beans and legumes.
    • Eat a healthy diet and exercise regularly to maintain proper weight.
    • Include leafy vegetables, citrus fruits, fatty fish, berries, yoghurt, apples, peaches, cauliflower, cabbage, broccoli, beans, and herbs.
    • De-stress yourself by meditating, reading books, taking a warm bubble bath or listening to soothing music.
    • Performing yoga may also help in improving both physical and mental health.
    • Maintain a healthy weight by performing regular low-strain exercises and eating healthy food.
    • Get optimal sleep; rest well.
    • Avoid smoking and alcohol consumption.
    • Avoid fast, fried, processed meats, refined carbs, and added sugars.

    Special Advise

    • Keep all of your doctor's and laboratory appointments.
    • Pregnancy testing is recommended prior to starting treatment with ACALABRUTINIB.

    Patients Concern

    Disease/Condition Glossary

    Cancer: Cancer is a genetic change in which our cells divide uncontrollably and spread into surrounding tissues. There are two types of cancer: benign (localized) and metastatic (spread to the whole body). Types of cancer include blood, lung, breast, etc. Cancer growth can be prevented by chemotherapy, radiation, and stem cell therapy.

    Mantle Cell lymphoma (MCL): Mantle Cell lymphoma (MCL) is an aggressive, rare form of non-Hodgkin lymphoma (NHL) that arises from cells originating in the “mantle zone.” The mantle zone is the outer ring of small lymphocytes surrounding the centre of a lymphatic nodule.

    FAQs

    How does ACALABRUTINIB work?

    ACALABRUTINIB contains Acalabrutinib, a tyrosine kinase inhibitor. Tyrosine kinases are enzymes in the body that send signals to cells, directing them to grow and divide. Acalabrutinib blocks these signals to cancer cells. Cancer cells die when their signals are interrupted. This could help to delay the progression of the cancer.

    What important things should I take care of while taking ACALABRUTINIB?

    While taking ACALABRUTINIB, make sure you visit your doctor at all the appointments to ensure that treatment works. Regular monitoring of blood and lipid tests and weight checks are required. An effective way of contraception should be used by both men and women while taking the ACALABRUTINIB.

    How to diagnosis of Mantle cell lymphoma (MCL)?

    Mantle cell lymphoma (MCL) is diagnosed by taking a biopsy of tumour tissue and examining the cells under a microscope.

    Can I take double dose to compensate missed dose?

    You can take the missed dose if you forget to take your acalabrutinib, which is less than 3 hours after your usual time. Then, take the next dose at the regular time. Do not take your missed dose if more than 3 hours have passed. Wait and take the next dose at the regular time. Do not take a double dose to make up for a missing one.

    Available Medicines for

    ACALABRUTINIB